“Our digital therapeutics empower you to alter the underlying mechanisms of disease—to target the thoughts, sensations, emotions and behaviors that define the experience of your condition—to help you achieve a healthier, happier life.”

Click Therapeutics is a biotechnology company at the forefront of developing, validating, and commercializing Software as Medical Devices (SaMD) to provide safe and effective digital treatments for individuals with unmet medical needs. Focusing on cognitive and neurobehavioral mechanisms, Click's Digital Therapeutics empower patients to initiate meaningful change, addressing the thoughts, sensations, emotions, and behaviors that define their conditions. These digital treatments are also designed to be used individually or in combination with biomedical therapies for a more integrated approach to care. At Click, the mission is to advance the science of change to help patients live healthier, happier lives. The company's digital therapeutics are developed with great care as regulated medical treatments adhering to the highest industry standards: FDA, ISO, and IEC. Click Therapeutics is transforming the way healthcare is delivered by empowering people to manage their conditions and improve their overall well-being through innovative digital solutions.

CT-132: Investigational Prescription Digital Therapeutic for Episodic Migraine

CT-132

CT-132 is an investigational prescription digital therapeutic for the prevention of episodic migraines in adults aged 18 years and older. It is intended to be used as adjunctive therapy to other treatments for migraines. CT-132 is not yet commercially available in the United States because it has not been approved by the FDA regarding its safety and effectiveness.

How CT-132 Works

Migraine pathophysiology includes hypersensitivity of the brain and increased pain signaling, leaving the brain at a greater risk for internal and external stimuli. Such stimuli often initiate crippling migraine attacks and severely affect one's daily life. CT-132 addresses this hypersensitivity through its proprietary 12-week clinical intervention. The company aims to adjust patients' responses to the variety of stimuli that may increase their brain hypersensitivity and, therefore, improve the patient's ability to carry on with their daily activities free from frequent migraines.

Clinical Validation CT-132 was clinically validated in the ReMMi-D pivotal trial, a decentralized, double-blind, randomized, and controlled study involving 568 participants. This trial evaluated the efficacy and safety of CT-132 in preventing episodic migraines, comparing it to a sham digital control intervention. The study included patients who were on common acute and preventive migraine medications.

The results of the ReMMi-D trial showed that CT-132 significantly reduced the number of monthly migraine days (MMDs). Patients treated with CT-132 had a decrease of 3.04 MMDs by the end of the 12-week treatment period, as opposed to a -0.9 MMD decrease in the control group (p=0.005). Moreover, patients on the treatment arm had

• Improvement in Migraine-Related Disability: Significant improvement in the Migraine Disability Assessment (MIDAS) (p=0.002).

• Enhanced Quality of Life: Improved scores in the Migraine-Specific Quality of Life (MSQ) questionnaire, as early as 4 weeks (p<0.001).

• Patient-Reported Outcomes: Patients reported significant improvement in their health as measured by the Patient Global Impression - Change (PGI-C) scale (p<0.001).

David B. Klein - CEO

David B. Klein is the CEO of the company. He has more than 20 years of experience in the life sciences industry. He was the Managing Director at Opus Point Partners where he played a key role in the creation, financing, and operation of over 10 science companies, including Cougar Biotechnology (acquired by J&J), Chelsea Therapeutics (acquired by Lundbeck), TG Therapeutics (TGTX), Assembly Biosciences (ASMB), Tracon Pharmaceuticals (TCON), Fortress Biotech (FBIO), and Alaunos Therapeutics (TCRT). Apart from the life sciences sector, Klein also serves as a Guest Faculty in the Biotechnology Program of Columbia University, NYU Stern School of Business, and Columbia Business School. He also has a rich experience working as a Senior Consultant for Pfizer and as a Strategic Advisor to both publicly traded and privately held life science companies. He is also the co-founder of Eli Klein Gallery, one of America's leading Chinese contemporary art galleries. He holds a B.A. from Brandeis University.

“We develop, validate, and commercialize software as prescription medical treatments for people with unmet medical needs. Through cognitive and neurobehavioral mechanisms, Click’s Digital Therapeutics™ enable change within individuals, and are designed to be used independently or in conjunction with biomedical treatments.”